Chemistry:Substituted tryptamine


Substituted tryptamines, or simply tryptamines, also known as serotonin analogues (i.e., 5-hydroxytryptamine analogues), are organic compounds which may be thought of as being derived from tryptamine itself. The molecular structures of all tryptamines contain an indole ring system, joined to an amino (NH2) group via an ethyl (−CH2–CH2−) sidechain. In substituted tryptamines, the indole ring, sidechain, and/or amino group are modified by substituting another group for one of the hydrogen (H) atoms.
Well-known tryptamines include serotonin, an important neurotransmitter, and melatonin, a hormone involved in regulating the sleep-wake cycle. Tryptamine alkaloids are found in fungi, plants and animals; and sometimes used by humans for the neurological or psychotropic effects of the substance. Prominent examples of tryptamine alkaloids include psilocybin (from "psilocybin mushrooms") and DMT. In South America, dimethyltryptamine is obtained from numerous plant sources, like chacruna, and it is often used in ayahuasca brews. Many synthetic tryptamines have also been made, including the migraine drug sumatriptan, and psychedelic drugs. A 2022 study has found the variety of tryptamines present in wild mushrooms may affect the therapeutic impact.[1]
The tryptamine structure, in particular its indole ring, may be part of the structure of some more complex compounds, for example cyclized tryptamines like LSD, ibogaine, harmaline, mitragynine and yohimbine. A thorough investigation of dozens of tryptamine compounds was published by Alexander Shulgin and Ann Shulgin in 1997 under the title TiHKAL (Tryptamines I Have Known and Loved).[2]
Use and effects
The doses, potencies, durations, and effects of psychedelic tryptamines have been reviewed by Alexander Shulgin and other authors.[3][4][5][6][2][7][8][9][10][11]
Ring-unsubstituted tryptamines
| Compound | Chemical name | Dose | Duration |
|---|---|---|---|
| Tryptamine (T) | Tryptamine | >100 mga | – |
| NMT | N-Methyltryptamine | Unknownb | – |
| NET | N-Ethyltryptamine | Unknown | Unknown |
| NiPT | N-Isopropyltryptamine | Unknown | Unknown |
| NsBT | N-sec-Butyltryptamine | 25–75 mg | "Short" |
| NtBT | N-tert-Butyltryptamine | 5–20 mg | Unknown |
| NAT | N-Amyltryptamine | >100 mg | – |
| NHT | N-Hexyltryptamine | >100 mg | – |
| DMT | N,N-Dimethyltryptamine | >350 mgc | – |
| DET | N,N-Diethyltryptamine | 50–150 mg | 2–4 hours |
| DPT | N,N-Dipropyltryptamine | 100–250 mg | 2–4 hours |
| DiPT | N,N-Diisopropyltryptamine | 25–100 mg (15–150 mg+) | 6–8 hours |
| DALT | N,N-Diallyltryptamine | 60–80 mg | <3 hours |
| DBT | N,N-Dibutyltryptamine | ≥100 mg | Unknown |
| DAT | N,N-Diamyltryptamine | Unknown | Unknown |
| DHT | N,N-Dihexyltryptamine | >100 mg | – |
| MET | N-Methyl-N-ethyltryptamine | 80–100 mg | Unknown |
| MPT | N-Methyl-N-propyltryptamine | >50 mg | Unknown |
| MiPT | N-Methyl-N-isopropyltryptamine | 10–25 mg | 3–4 hours |
| MBT | N-Methyl-N-butyltryptamine | 250–400 mg | 4–6 hours |
| MsBT | N-Methyl-N-sec-butyltryptamine | 250–400 mg | Unknown |
| EPT | N-Ethyl-N-propyltryptamine | Unknown | Unknown |
| EiPT | N-Ethyl-N-isopropyltryptamine | 24–40 mg | 4–6 hours |
| PiPT | N-Propyl-N-isopropyltryptamine | Unknown | Unknown |
| Pyr-T | N,N-Tetramethylenetryptamine | Unknown | Unknown |
4-Hydroxytryptamines
| Compound | Chemical name | Dose | Duration | |
|---|---|---|---|---|
| 4-HT (4-HO-T) | 4-Hydroxytryptamine | Unknown | Unknown | |
| Norbaeocystin (4-PO-T) | 4-Phosphoryloxytryptamine | Unknown | Unknown | |
| Norpsilocin (4-HO-NMT) | 4-Hydroxy-N-methyltryptamine | Unknown | Unknown | |
| Baeocystin (4-PO-NMT) | 4-Phosphoryloxy-N-methyltryptamine | 4–10 mga | Unknown | |
| Psilocin (4-HO-DMT) | 4-Hydroxy-N,N-dimethyltryptamine | 10–20 mg (5–40 mg+) | 3–6 hours | |
| Psilocybin (4-PO-DMT) | 4-Phosphoryloxy-N,N-dimethyltryptamine | 10–20 mg (5–40 mg+) | 3–6 hours | |
| 4-AcO-DMT (psilacetin) | 4-Acetoxy-N,N-dimethyltryptamine | Unknown | Unknown | |
| 4-PrO-DMT | 4-Propionyloxy-N,N-dimethyltryptamine | Unknown | Unknown | |
| 4-HO-DET (ethocin) | 4-Hydroxy-N,N-diethyltryptamine | 10–25 mg | 4–6 hours | |
| Ethocybin (4-PO-DET) | 4-Phosphoryloxy-N,N-diethyltryptamine | 15–30 mg | 4–6 hours | |
| 4-HO-DPT (deprocin) | 4-Hydroxy-N,N-dipropyltryptamine | >20 mg | 5–8 hours | |
| 4-HO-DiPT (iprocin) | 4-Hydroxy-N,N-diisopropyltryptamine | 12–20 mg (3–30 mg+) | 2–3 hours | |
| 4-AcO-DiPT (ipracetin) | 4-Acetoxy-N,N-diisopropyltryptamine | 6–10 mg | Unknown | |
| Luvesilocin (4-GO-DiPT) | 4-Glutaryloxy-N,N-diisopropyltryptamine | Unknownb | Unknownb | |
| 4-HO-DALT (daltocin) | 4-Hydroxy-N,N-diallyltryptamine | Unknown | Unknown | |
| 4-HO-DBT | 4-Hydroxy-N,N-dibutyltryptamine | >20 mg | Unknown | |
| 4-HO-DiBT | 4-Hydroxy-N,N-diisobutyltryptamine | >20 mg | Unknown | |
| 4-HO-DtBT | 4-HydroxyN,N-di-tert-butyltryptamine | Unknown | Unknown | |
| 4-HO-MET (metocin) | 4-Hydroxy-N-methyl-N-ethyltryptamine | 10–20 mg (2–45 mg+) | 4–6 hours | |
| 4-HO-MPT (meprocin) | 4-Hydroxy-N-methyl-N-propyltryptamine | 8–30 mg | Unknown | |
| 4-HO-MiPT (miprocin) | 4-Hydroxy-N-methyl-N-isopropyltryptamine | 12–25 mg (6–30 mg) | 4–6 hours | |
| 4-HO-MALT (maltocin) | 4-Hydorxy-N-methyl-N-allyltryptamine | Unknown | Unknown | |
| 4-HO-MtBT | 4-Hydroxy-N-methyl-N-tert-butyltryptamine | >15 mg | Unknown | |
| 4-HO-EPT (eprocin) | 4-Hydroxy-N-ethyl-N-propyltryptamine | Unknown | Unknown | |
| 4-HO-EiPT | 4-Hydroxy-N-ethyl-N-isopropyltryptamine | Unknown | Unknown | |
| 4-HO-PiPT (piprocin) | 4-Hydroxy-N-propyl-N-isopropyltryptamine | Unknown | Unknown | |
| 4-HO-TMT | 4-Hydroxy-N,N,N-trimethyltryptamine | Unknown | Unknown | |
| Aeruginascin (4-PO-TMT) | 4-Phosphoryloxy-N,N,N-trimethyltryptamine | Unknown | Unknown | |
| 4-HO-pyr-T | 4-Hydroxy-N,N-tetramethylenetryptamine | >20 mg | Unknown | |
| Footnotes: a = Baeocystin has conflicting reports, some say that it's active and some say that it's inactive. b = Luvesilocin is known to be active subcutaneously at doses of 5 to 40 mg with an average duration of 3.6 hours. Refs: [3][4][2][7][8][9][11] Individual: [12][13][14][15] | ||||
5-Hydroxytryptamines
| Compound | Chemical name | Dose | Duration | |
|---|---|---|---|---|
| Serotonin (5-HT, 5-HO-T) | 5-Hydroxytryptamine | >100 mga | – | |
| N-Methylserotonin (norbufotenin; 5-HO-NMT) | 5-Hydroxy-N-methyltryptamine | Unknown | Unknown | |
| Bufotenin (5-HO-DMT) | 5-Hydroxy-N,N-dimethyltryptamine | >100 mgb | – | |
| O-Acetylbufotenin (5-AcO-DMT) | 5-Acetoxy-N,N-dimethyltryptamine | Unknown | Unknown | |
| O-Pivalylbufotenin (5-t-BuCO-DMT) | 5-Pivaloxy-N,N-dimethyltryptamine | Unknown | Unknown | |
| 5-HO-DET | 5-Hydroxy-N,N-diethyltryptamine | Unknown | Unknown | |
| 5-HO-DPT (DiPS, NDPS) | 5-Hydroxy-N,N-dipropyltryptamine | Unknown | Unknown | |
| 5-HO-DiPT | 5-Hydroxy-N,N-diisopropyltryptamine | Unknown | Unknown | |
| Footnotes: a = Serotonin does not cross the blood–brain barrier and is not psychoactive. b = Bufotenin is not orally active, but is active at intravenously at doses of 8 to 16 mg with a duration of 1 to 2 hours and is active via insufflation and other parenteral routes. Refs: [3][4][2][11] Individual: [16][17][18][19] | ||||
5-Methoxytryptamines
| Compound | Chemical name | Dose | Duration | |
|---|---|---|---|---|
| 5-MT (5-MeO-T) | 5-Methoxytryptamine | Unknown | Unknown | |
| 5-MeO-NMT | 5-Methoxy-N-methyltryptamine | Unknown | Unknown | |
| 5-MeO-NET | 5-Methoxy-N-ethyltryptamine | Unknown | Unknown | |
| 5-MeO-NiPT | 5-Methoxy-N-isopropyltryptamine | Unknown | Unknown | |
| 5-MeO-DMT (mebufotenin) | 5-Methoxy-N,N-dimethyltryptamine | >35 mga | – | |
| 5-MeO-DET | 5-Methoxy-N,N-diethyltryptamine | 1–3 mg | 3–4 hours | |
| 5-MeO-DPT | 5-Methoxy-N,N-dipropyltryptamine | 6–10 mg | 2–4 hours | |
| 5-MeO-DiPT | 5-Methoxy-N,N-diisopropyltryptamine | 6–12 mg | 4–8 hours | |
| 5-MeO-DALT | 5-Methoxy-N,N-diallyltryptamine | 12–25 mg | 2–4 hours | |
| 5-MeO-DBT | 5-Methoxy-N,N-dibutyltryptamine | Unknown | Unknown | |
| 5-MeO-DsBT | 5-Methoxy-N,N-di-sec-butyltryptamine | Unknown | Unknown | |
| 5-MeO-MET | 5-Methoxy-N-methyl-N-ethyltryptamine | Unknown | Unknown | |
| 5-MeO-MPT | 5-Methoxy-N-methyl-N-propyltryptamine | Unknown | Unknown | |
| 5-MeO-MiPT | 5-Methoxy-N-methyl-N-isopropyltryptamine | 4–6 mg (0.5–20 mg+) | 4–6 hours | |
| 5-MeO-MALT | 5-Methoxy-N-methyl-N-allyltryptamine | Unknown | Unknown | |
| 5-MeO-EPT | 5-Methoxy-N-ethyl-N-propyltryptamine | Unknown | Unknown | |
| 5-MeO-EiPT | 5-Methoxy-N-ethyl-N-isopropyltryptamine | Unknown | Unknown | |
| 5-MeO-PiPT | 5-Methoxy-N-propyl-N-isopropyltryptamine | Unknown | Unknown | |
| ASR-3001 (5-MeO-iPALT) | 5-Methoxy-N-isopropyl-N-allyltryptamine | 8–14 mg | 1.5–2.5 hours | |
| 5-MeO-pyr-T | 5-Methoxy-N,N-tetramethylenetryptamine | 0.5–2 mg | Several hours | |
| Melatonin (5-MeO-NAcT) | 5-Methoxy-N-acetyltryptamine | 1–10 mgb | A few hours | |
| Footnotes: a = 5-MeO-DMT is not orally active, but is active at a dose of 2 to 20 mg smoked or 2 to 3 mg intravenously, with a duration of 5 to 20 minutes. Also orally active with an MAOI at doses of 10 to 25 mg. b = Melatonin is not a psychedelic but a hypnotic and is non-hallucinogenic at doses of up to 1,200 mg. Refs: [3][4][2][7][8][9][11] Individual: [13][20] | ||||
α-Alkyltryptamines
| Compound | Chemical name | Dose | Duration | |
|---|---|---|---|---|
| AMT (α-methyl-T; Indopan)a | α-Methyltryptamine | 15–40 mg | 12–16 hours | |
| AET (α-ethyl-T; etryptamine; Monase)b | α-Ethyltryptamine | 100–160 mg | 6–8 hours | |
| α,N-DMT (N-methyl-AMT)c | α-Methyl-N-methyltryptamine | 50–100 mg | 6–8 hours | |
| α,N,N-TMT (N,N-dimethyl-AMT) | α,N,N-Trimethyltryptamine | Unknownd | Unknown | |
| 2,α-DMT (2-methyl-AMT) | 2-Methyl-α-methyltryptamine | 300–500 mg | 7–10 hours | |
| 4-HO-AMT | 4-Hydroxy-α-methyltryptamine | 15–20 mg+ | Unknown | |
| 4-Methyl-AMT | 4-Methyl-α-methyltryptamine | 20–60 mg+ | Unknown | |
| 5-Fluoro-AMT | 5-Fluoro-α-methyltryptamine | 25 mg+ | >9 hours | |
| 6-Fluoro-AMT | 6-Fluoro-α-methyltryptamine | 25–75 mg | "Long" | |
| α-Methylserotonin (AMS; 5-HO-AMT) | α-Methyl-5-hydroxytryptamine | Unknown | Unknown | |
| α,O-DMS (5-MeO-AMT) | α-Methyl-5-methoxytryptamine | 2.5–5 mg (0.5–15 mg) | 12–18 hours | |
| α,N,O-TMS (5-MeO-N-methyl-AMT) | α-Methyl-5-methoxy-N-methyltryptamine | 10–20 mg | 6–8 hours | |
| α,N,N,O-TeMS (5-MeO-N,N-dimethyl-AMT) | 5-Methoxy-α,N,N-trimethyltryptamine | Unknown | Unknown | |
| 5-MeO-AET | α-Ethyl-5-methoxytryptamine | ~70 mg | Several hours | |
| Bk-NM-AMT (β-keto-N-methyl-AMT)e | α-Methyl-β-keto-N-methyltryptamine | Unknown | Unknown | |
| Footnotes: a = AMT is a not only a psychedelic but is also a stimulant and entactogen. b = AET is an entactogen and stimulant and is not a psychedelic. c = α,N-DMT is a stimulant and is not a psychedelic or entactogen. d = α,N,N-TMT has been reported to be an active psychedelic orally but to be much less potent than AMT. e = Bk-NM-AMT is expected to be an entactogen and stimulant but not a psychedelic. Refs: [3][4][2][7][8][11] Individual: [21][22] | ||||
Other tryptamines
| Compound | Chemical name | Dose | Duration | |
|---|---|---|---|---|
| 2-Methyl-DMT | 2-Methyl-N,N-dimethyltryptamine | 50–100 mg | 4–6 hours | |
| 2-Methyl-DET | 2-Methyl-N,N-diethyltryptamine | 80–120 mg | 6–8 hours | |
| 4-MeO-MiPT | 4-Methoxy-N-methyl-N-isopropyltryptamines | 20–30 mg | 4–6 hours | |
| 4,5-MDO-DMT | 4,5-Methylenedioxy-N,N-dimethyltryptamine | Unknown | Unknown | |
| 4,5-MDO-DiPT | 4,5-Methylenedioxy-N,N-diisopropyltryptamine | >25 mg | Unknown | |
| 5-Fluoro-DMT | 5-Fluoro-N,N-dimethyltryptamine | Unknown | Unknown | |
| 5-Chloro-DMT | 5-Chloro-N,N-dimethyltryptamine | Unknown | Unknown | |
| 5-Bromo-DMT | 5-Bromo-N,N-dimethyltryptamine | Unknowna | Unknown | |
| Bretisilocin (5-fluoro-MET) | 5-Fluoro-N-methyl-N-ethyltryptamine | Unknownb | Unknownb | |
| 5-MeO-2-TMT | 5-Methoxy-2-methyl-N,N-dimethyltryptamine | 75–150 mg | 5–10 hours | |
| 5-MeS-DMT | 5-Methylthio-N,N-dimethyltryptamine | Unknownc | Unknownc | |
| 5,6-MeO-MiPT | 5,6-Dimethoxy-N-methyl-N-isopropyltryptamine | >75 mg | Unknown | |
| 5,6-MDO-DMT | 5,6-Methylenedioxy-N,N-dimethyltryptamine | >5 mg | Unknown | |
| 5,6-MDO-DiPT | 5,6-Methylenedioxy-N,N-diisopropyltryptamine | Unknown | Unknown | |
| 5,6-MDO-MiPT | 5,6-Methylenedioxy-N-methyl-N-isopropyltryptamine | >50–60 mg | Unknown | |
| 6-Fluoro-DMT | 6-Fluoro-N,N-dimethyltryptamine | Unknown | Unknown | |
| 6-Fluoro-DET | 6-Fluoro-N,N-diethyltryptamine | >80 mg | Unknown | |
| 6-HO-DMT | 6-Hydroxy-N,N-dimethyltryptamine | >80 mg | Unknown | |
| 6-MeO-DiPT | 6-Methoxy-N,N-diisopropyltryptamine | >50 mg | Unknown | |
| 6-MeO-MiPT | 6-Methoxy-N-methyl-N-isopropyltryptamine | >50 mg | Unknown | |
| 7-MeO-DiPT | 7-Methoxy-N,N-diisopropyltryptamine | >70 mg | Unknown | |
| 7-MeO-MiPT | 7-Methoxy-N-methyl-N-isopropyltryptamine | >70 mg | Unknown | |
| Footnotes: a 5-Bromo-DMT is active via smoking at a dose of 20 to 50 mg. b = Bretisilocin is active intravenously with a dose range of 10 to 20 mg and a duration of 60 to 90 minutes. c = 5-MeS-DMT's oral dose and duration are unknown, but smoked the dose is 15 to 30 mg and the duration is <1 hour. Refs: [3][4][2][9][11] Individual: [23][24] | ||||
Interactions
List of substituted tryptamines
| Structure | Name | Origin | Ring sub. | RN1 | RN2 | Chemical name | CAS # |
|---|---|---|---|---|---|---|---|
| Tryptamine (T) | Animals, plants, fungi | H | H | H | 3-(2-aminoethyl)indole / 2-(1H-indol-3-yl)ethanamine | 61-54-1 | |
| NMT | Plants | H | H | CH3 | N-methyltryptamine | 61-49-4 | |
| 2-HO-NMT | Plants | 2-OH | H | CH3 | 2-hydroxy-N-methyltryptamine | 106987-89-7 | |
| 5-MeO-NMT | Plants | 5-OCH3 | H | CH3 | 5-methoxy-N-methyltryptamine | 2009-03-2 | |
| Serotonin (5-HT) | Animals, plants | 5-OH | H | H | 5-hydroxytryptamine | 50-67-9 | |
| N-Methylserotonin (NMS; norbufotenin; 5-HO-NMT) | Plants | 5-OH | H | CH3 | 5-hydroxy-N-methyltryptamine | 1134-01-6 | |
| Bufotenin (5-HO-DMT) | Animals, plants, fungi | 5-OH | CH3 | CH3 | 5-hydroxy-N,N-dimethyltryptamine | 487-93-4 | |
| Bufotenidine (5-HTQ) | Amphibians | 5-O− | (CH3)3 | 3-[2-(trimethylazaniumyl)ethyl]-1H-indol-5-olate | 487-91-2 | ||
| Bufoviridine (5-SO-DMT) | Amphibians | 5-SO | CH3 | CH3 | 5-sulfooxy-N,N-dimethyltryptamine | 16369-08-7 | |
| Melatonin (5-MeO-NAcT) | Animals, plants, microbes | 5-OCH3 | H | O=C-CH3 | 5-methoxy-N-acetyltryptamine | 73-31-4 | |
| N-Acetylserotonin (NAS; normelatonin; 5-HO-NAcT) | Animals | 5-OH | H | O=C-CH3 | 5-hydroxy-N-acetyltryptamine | 1210-83-9 | |
| 6-Hydroxymelatonin | Animals | 5-OCH3, 6-OH | H | O=C-CH3 | N-[2-(6-Hydroxy-5-methoxy-1H-indol-3-yl)ethyl]acetamide | 2208-41-5 | |
| 4-Hydroxytryptamine (4-HT) | Fungi | 4-OH | H | H | 4-hydroxytryptamine | 570-14-9 | |
| 4-HO-NMT | Fungi | 4-OH | H | CH3 | 4-hydroxy-N-methyltryptamine | 28363-70-4 | |
| Psilocin (4-HO-DMT) | Fungi | 4-OH | CH3 | CH3 | 4-hydroxy-N,N-dimethyltryptamine | 520-53-6 | |
| 4-HO-TMT | Fungi | 4-OH | CH3 | CH3 | 4-hydroxy-N,N,N-trimethyltryptammonium | 262285-41-6 | |
| Norbaeocystin (4-PO-T) | Fungi | 4-OPO3H2 | H | H | 4-phosphoryloxy-tryptamine | 21420-59-7 | |
| Baeocystin (4-PO-NMT) | Fungi | 4-OPO3H2 | H | CH3 | 4-phosphoryloxy-N-methyl-tryptamine | 21420-58-6 | |
| Psilocybin (4-PO-DMT) | Fungi | 4-OPO3H2 | CH3 | CH3 | 4-phosphoryloxy-N,N-dimethyltryptamine | 520-52-5 | |
| Aeruginascin (4-PO-TMT) | Fungi | 4-OPO3H2 | (CH3)3 | [3-[2-(trimethylazaniumyl)ethyl]-1H-indol-4-yl] hydrogen phosphate | 114264-95-8 | ||
| DMT | Animals, plants | H | CH3 | CH3 | N,N-dimethyltryptamine | 61-50-7 | |
| Lespedamine (1-MeO-DMT) | Plants | 1-OCH3 | CH3 | CH3 | 1-methoxy-N,N-dimethyltryptamine | 4335-93-7 | |
| 5-MeO-DMT (mebufotenin) | Animals, plants | 5-OCH3 | CH3 | CH3 | 5-methoxy-N,N-dimethyltryptamine | 1019-45-0 | |
| 5-Bromo-DMT | Marine sponges, invertebrates | 5-Br | CH3 | CH3 | 5-bromo-N,N-dimethyltryptamine | 17274-65-6 | |
| 6-Bromotryptamine | Marine invertebrates | 6-Br | H | H | 6-bromotryptamine | 96624-18-9 | |
| 5,6-Dibromotryptamine | Marine invertebrates | 5,6-Br | H | H | 5,6-dibromotryptamine | ||
| 5,6-Dibromo-NMT | Marine invertebrates | 5,6-Br | H | CH3 | 5,6-dibromo-N-methyltryptamine | ||
| 5,6-Dibromo-DMT | Marine sponges, invertebrates | 5,6-Br | CH3 | CH3 | 5,6-dibromo-N,N-dimethyltryptamine | 72853-80-6 | |
| Desformylflustrabromine (dFBr) | Marine invertebrates | 2-(α,α-dimethylallyl), 6-Br | H | CH3 | 2-[6-bromo-2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl]-N-methylethanamine | 474657-72-2 | |
| Convolutindole A | Marine invertebrates | 2,4,6-Br, 1,7-OCH3 | CH3 | CH3 | 1,7-dimethoxy-2,4,6-tribromo-N,N-dimethyltryptamine | 443356-86-3 | |
| Error creating thumbnail: Unable to save thumbnail to destination | Acetryptine (5-AT) | artificial | 5-COCH3 | H | H | 5-Acetyltryptamine | 3551-18-6 |
| 5-BT | artificial | 5-OCH2C6H5 | H | H | 5-Benzyloxytryptamine | 20776-45-8 | |
| 5-CT | artificial | 5-CONH2 | H | H | 5-Carboxamidotryptamine | 74885-09-9 | |
| 5-NOT | artificial | 5-O(CH2)8CH3 | H | H | 5-Nonyloxytryptamine | 157798-12-4 | |
| 2-Methyl-5-hydroxytryptamine | artificial | 2-CH3, 5-OH | H | H | 3-(2-aminoethyl)-2-methyl-1H-indol-5-ol | 78263-90-8 | |
| NET | artificial | H | H | CH2CH3 | N-ethyltryptamine | 61-53-0 | |
| NiPT | artificial | H | H | CH(CH3)2 | N-isopropyltryptamine | 14121-10-9 | |
| NcPT | artificial | H | H | C3H5 | N-cyclopropyltryptamine | ||
| NsBT | artificial | H | H | CH(CH3)CH2CH3 | N-sec-butyltryptamine | ||
| NtBT | artificial | H | H | C(CH3)3 | N-[2-(1H-indol-3-yl)ethyl]-2-methylpropan-2-amine | 1344092-44-9 | |
| N-Benzyltryptamine (NBnT) | artificial | H | H | CH2C6H5 | N-benzyltryptamine | 15741-79-4 | |
| 4-HO-NBnT | artificial | 4-OH | H | CH2C6H5 | 4-hydroxy-N-benzyltryptamine | ||
| 5-MeO-NBnT | artificial | 5-OCH3 | H | CH2C6H5 | 5-methoxy-N-benzyltryptamine | 25100-31-6 | |
| 5-MeO-T-NBOMe | artificial | 5-OCH3 | H | CH2C6H4(o-OCH3) | 5-methoxy-N-(ortho-methoxybenzyl)tryptamine | 1335331-37-7 | |
| 5-MT-NB3OMe [25] | artificial | 5-OCH3 | H | CH2C6H4(m-OCH3) | 5-methoxy-N-(meta-methoxybenzyl)tryptamine | 1648553-42-7 | |
| 5-MeO-NBpBrT | artificial | 5-OCH3 | H | CH2C6H4(p-Br) | N-(4-Bromobenzyl)-2-(5-methoxy-1H-indol-3-yl)ethanamine | 155639-13-7 | |
| 5-MeO-34MPEMT [26] | artificial | 5-OCH3 | CH3 | CH2CH2C6H3(p,m-OCH3) | N-methyl-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(5-methoxy-1H-indol-3-yl)ethanamine | ||
| Idalopirdine | artificial | 6-F | H | CH2C6H4(m-OCH2CF2CF2H) | 2-(6-Fluoro-1H-indol-3-yl)-N-(3-(2,2,3,3-tetrafluoro-propoxy)benzyl)ethanamine | 467459-31-0 | |
| Z2876442907[27] | artificial | 4-CH3 | H | CH2(C3HNS)-COOCH2CH3 | ethyl 2-({[2-(4-methyl-1H-indol-3-yl)ethyl]amino}methyl)-1,3-thiazole-5-carboxylate | ||
| Cis-2',5'-dimethyl-4-HO-azt-T [28] | artificial | 4-OH | cis-(CHCH3)CH2(CHCH3) | 3-{2-[(2R,4S)-2,4-dimethylazetidin-1-yl]ethyl}-1H-indol-4-ol | |||
| Pyr-T | artificial | H | (CH2)4 | 3-[2-(Pyrrolidin-1-yl)ethyl]-1H-indole | 14008-96-9 | ||
| 4-HO-pyr-T | artificial | 4-OH | (CH2)4 | 3-[2-(Pyrrolidin-1-yl)ethyl]-1H-indol-4-ol | 63097-26-7 | ||
| Cis-2',5'-dimethyl-4-HO-pyr-T [28] | artificial | 4-OH | cis-(CHCH3)CH2CH2(CHCH3) | 3-{2-[(2R,5S)-2,5-dimethylpyrrolidin-1-yl]ethyl}-1H-indol-4-ol | |||
| 5-MeO-pyr-T | artificial | 5-OCH3 | (CH2)4 | 5-Methoxy-3-[2-(pyrrolidin-1-yl)ethyl]-1H-indole | 3949-14-2 | ||
| 4-F-5-MeO-pyr-T | artificial | 4-F-5-OCH3 | (CH2)4 | 4-Fluoro-5-methoxy-3-(2-pyrrolidin-1-ylethyl)-1H-indole | 344790-93-8 | ||
| Indolylethylfentanyl | artificial | H | (CH2)5-4-N(COCH2CH3)C6H5 | N-[1-[2-(1H-indol-3-yl)ethyl]piperidin-4-yl]-N-phenylpropanamide | 58399-46-5 | ||
| MET | artificial | H | CH3 | CH2CH3 | N-Methyl-N-ethyltryptamine | 5599-69-9 | |
| MPT | artificial | H | CH3 | CH2CH2CH3 | N-Methyl-N-propyltryptamine | 850032-72-3 | |
| MiPT | artificial | H | CH3 | CH(CH3)2 | N-Methyl-N-isopropyltryptamine | 96096-52-5 | |
| McPT | artificial | H | CH3 | C3H5 | N-Methyl-N-cyclopropyltryptamine | 1373918-63-8 | |
| EcPT | artificial | H | CH2CH3 | C3H5 | N-ethyl-N-cyclopropyltryptamine | ||
| PcPT | artificial | H | CH2CH2CH3 | C3H5 | N-propyl-N-cyclopropyltryptamine | ||
| iPcPT | artificial | H | CH(CH3)2 | C3H5 | N-isopropyl-N-cyclopropyltryptamine | ||
| DcPT | artificial | H | C3H5 | C3H5 | N,N-dicyclopropyltryptamine | 1373918-62-7 | |
| MBT | artificial | H | CH3 | (CH2)3CH3 | N-Methyl-N-butyltryptamine | 848130-12-1 | |
| MsBT | artificial | H | CH3 | CH(CH3)CH2CH3 | N-Methyl-N-sec-butyltryptamine | ||
| MiBT | artificial | H | CH3 | CH2CH(CH3)2 | N-Methyl-N-iso-butyltryptamine | ||
| McPMT | artificial | H | CH3 | CH2C3H5 | N-Methyl-N-(cyclopropylmethyl)tryptamine | ||
| DET | artificial | H | CH2CH3 | CH2CH3 | N,N-diethyltryptamine | 61-51-8 | |
| EPT | artificial | H | CH2CH3 | CH2CH2CH3 | N-Ethyl-N-propyltryptamine | 850032-68-7 | |
| EiPT | artificial | H | CH2CH3 | CH(CH3)2 | N-Ethyl-N-isopropyltryptamine | 848130-11-0 | |
| DPT | artificial | H | CH2CH2CH3 | CH2CH2CH3 | N,N-dipropyltryptamine | 61-52-9 | |
| PiPT | artificial | H | CH2CH2CH3 | CH(CH3)2 | N-Propyl-N-isopropyltryptamine | 1354632-00-0 | |
| DiPT | artificial | H | CH(CH3)2 | CH(CH3)2 | N,N-diisopropyltryptamine | 14780-24-6 | |
| EBT | artificial | H | CH2CH3 | (CH2)3CH3 | N-ethyl-N-butyltryptamine | ||
| PBT | artificial | H | CH2CH2CH3 | (CH2)3CH3 | N-propyl-N-butyltryptamine | ||
| iPsBT | artificial | H | CH(CH3)2 | CH(CH3)CH2CH3 | N-isopropyl-N-sec-butyltryptamine | ||
| DBT | artificial | H | (CH2)3CH3 | (CH2)3CH3 | N,N-dibutyltryptamine | 15741-77-2 | |
| DiBT | artificial | H | CH2CH(CH3)2 | CH2CH(CH3)2 | N,N-diisobutyltryptamine | 63938-64-7 | |
| DsBT | artificial | H | CH(CH3)CH2CH3 | CH(CH3)CH2CH3 | N,N-disecbutyltryptamine | ||
| MALT | artificial | H | CH3 | H2C=CH-CH2 | N-methyl-N-allyltryptamine | 1366416-29-6 | |
| DALT | artificial | H | H2C=CH-CH2 | H2C=CH-CH2 | N,N-diallyltryptamine | 60676-77-9 | |
| iPALT (ALiPT) | artificial | H | H2C=CH-CH2 | CH(CH3)2 | N-allyl-N-isopropyltryptamine | ||
| 2-Methyl-DMT | artificial | 2-CH3 | CH3 | CH3 | (2-(2-methyl-1H-indol-3-yl)-1-methyl-ethyl)dimethylamine | 1080-95-1 | |
| 2-Methyl-DET | artificial | 2-CH3 | CH2CH3 | CH2CH3 | N,N-Diethyl-2-(2-methyl-1H-indol-3-yl)ethan-1-amine | 26628-88-6 | |
| 4-Amino-DMT [29] | artificial | 4-NH2 | CH3 | CH3 | 4-amino-N,N-dimethyltryptamine | 60331-61-5 | |
| 4-Methyl-DMT | artificial | 4-CH3 | CH3 | CH3 | 4,N,N-trimethyltryptamine | 28289-23-8 | |
| 4-MeO-DMT | artificial | 4-OCH3 | CH3 | CH3 | 4-methoxy-N,N-dimethyltryptamine | 3965-97-7 | |
| 4-MeO-MiPT | artificial | 4-OCH3 | CH3 | CH(CH3)2 | 4-methoxy-N-methyl-N-isopropyltryptamine | 96096-53-6 | |
| 4-MeO-DiPT | artificial | 4-OCH3 | CH(CH3)2 | CH(CH3)2 | 4-methoxy-N,N-diisopropyltryptamine | ||
| 4-AcO-DMT | artificial | 4-OCOCH3 | CH3 | CH3 | 4-acetoxy-N,N-dimethyltryptamine | 92292-84-7 | |
| 4-PrO-DMT | artificial | 4-OCOCH2CH3 | CH3 | CH3 | 4-propionyloxy-N,N-dimethyltryptamine | 1373882-11-1 | |
| 4-GO-DMT (RE109; FT-109) | artificial | 4-OCO(CH2)3COOH | CH3 | CH3 | 4-glutaryloxy-N,N-dimethyltryptamine | ||
| 4-HO-MET | artificial | 4-OH | CH3 | CH2CH3 | 4-hydroxy-N-methyl-N-ethyltryptamine | 77872-41-4 | |
| 4-AcO-MET | artificial | 4-OCOCH3 | CH3 | CH2CH3 | 4-acetoxy-N-methyl-N-ethyltryptamine | 1445751-40-5 | |
| 4-PO-MET | artificial | 4-OPO3H2 | CH3 | CH2CH3 | 4-phosphoryloxy-N-methyl-N-ethyltryptamine | ||
| 4-HO-DET | artificial | 4-OH | CH2CH3 | CH2CH3 | 4-hydroxy-N,N-diethyltryptamine | 22204-89-3 | |
| 4-AcO-DET | artificial | 4-OCOCH3 | CH2CH3 | CH2CH3 | 4-acetoxy-N,N-diethyltryptamine | 1135424-15-5 | |
| 4-PO-DET | artificial | 4-OPO3H2 | CH2CH3 | CH2CH3 | 4-phosphoryloxy-N,N-diethyltryptamine | 60480-02-6 | |
| 4-HO-EPT | artificial | 4-OH | CH2CH3 | CH2CH2CH3 | 4-hydroxy-N-ethyl-N-propyltryptamine | 2595431-59-5 | |
| 4-PO-EPT | artificial | 4-OPO3H2 | CH2CH3 | CH2CH2CH3 | 4-phosphoryloxy-N-ethyl-N-propyltryptamine | ||
| 4-AcO-EiPT | artificial | 4-OCOCH3 | CH2CH3 | CH(CH3)2 | 4-acetoxy-N-ethyl-N-isopropyltryptamine | ||
| 4-HO-MPT | artificial | 4-OH | CH3 | CH2CH2CH3 | 4-hydroxy-N-methyl-N-propyltryptamine | 763035-03-6 | |
| 4-HO-MiPT | artificial | 4-OH | CH(CH3)2 | CH3 | 4-hydroxy-N-isopropyl-N-methyltryptamine | 77872-43-6 | |
| 4-AcO-MiPT | artificial | 4-OCOCH3 | CH3 | CH(CH3)2 | 4-acetoxy-N-methyl-N-isopropyltryptamine | 1024612-25-6 | |
| 4-HO-MALT[30] | artificial | 4-OH | CH3 | H2C=CH-CH2 | 4-hydroxy-N-Methyl-N-allyltryptamine | ||
| 4-AcO-MALT[31] | artificial | 4-OCOCH3 | CH3 | H2C=CH-CH2 | 4-acetoxy-N-Methyl-N-allyltryptamine | ||
| 4-HO-NALT[32] | artificial | 4-OH | H | H2C=CH-CH2 | 4-hydroxy-N-allyltryptamine | ||
| 4-HO-MsBT | artificial | 4-OH | CH(CH3)CH2CH3 | CH3 | 4-hydroxy-N-sec-butyl-N-methyltryptamine | ||
| 4-HO-EiBT | artificial[33] | 4-OH | CH2CH(CH3)2 | CH2CH3 | 4-hydroxy-N-iso-butyl-N-ethyltryptamine | ||
| 4-HO-McPT | artificial | 4-OH | C3H5 | CH3 | 4-hydroxy-N-cyclopropyl-N-methyltryptamine | 2883663-05-4 | |
| 4-HO-McPeT | artificial | 4-OH | C5H9 | CH3 | 4-hydroxy-N-cyclopentyl-N-methyltryptamine | 77872-48-1 | |
| 4-HO-McPMT [34] | artificial | 4-OH | CH2C3H5 | CH3 | 4-hydroxy-N-cyclopropylmethyl-N-methyltryptamine | ||
| 4-HO-DPT | artificial | 4-OH | CH2CH2CH3 | CH2CH2CH3 | 4-hydroxy-N,N-dipropyltryptamine | 63065-88-3 | |
| 4-AcO-DPT | artificial | 4-OCOCH3 | CH2CH2CH3 | CH2CH2CH3 | 4-acetoxy-N,N-dipropyltryptamine | 1445751-75-6 | |
| 4-HO-PiPT | artificial | 4-OH | CH2CH2CH3 | CH(CH3)2 | 4-hydroxy-N-propyl-N-isopropyltryptamine | ||
| 4-AcO-PiPT | artificial | 4-OCOCH3 | CH2CH2CH3 | CH(CH3)2 | 4-acetoxy-N-propyl-N-isopropyltryptamine | ||
| 4-HO-DiPT | artificial | 4-OH | CH(CH3)2 | CH(CH3)2 | 4-hydroxy-N,N-diisopropyltryptamine | 132328-45-1 | |
| 4-AcO-DiPT | artificial | 4-OCOCH3 | CH(CH3)2 | CH(CH3)2 | 4-acetoxy-N,N-diisopropyltryptamine | 936015-60-0 | |
| 4-PrO-DiPT | artificial | 4-OCOCH2CH3 | CH(CH3)2 | CH(CH3)2 | 4-propionyloxy-N,N-diisopropyltryptamine | 1373882-13-3 | |
| Luvesilocin (RE104; FT-104) | artificial | 4-OCO(CH2)3COOH | CH(CH3)2 | CH(CH3)2 | 4-glutaryloxy-N,N-diisopropyltryptamine | ||
| 4-PO-DiPT | artificial | 4-OPO3H2 | CH(CH3)2 | CH(CH3)2 | 4-phosphoryloxy-N,N-diisopropyltryptamine | 1373882-09-7 | |
| 4-HO-DALT | artificial | 4-OH | H2C=CH-CH2 | H2C=CH-CH2 | 4-hydroxy-N,N-diallyltryptamine | 2173386-70-2 | |
| 4-AcO-DALT | artificial | 4-OCOCH3 | H2C=CH-CH2 | H2C=CH-CH2 | 4-acetoxy-N,N-diallyltryptamine | 1445751-71-2 | |
| 4-HO-DBT | artificial | 4-OH | (CH2)3CH3 | (CH2)3CH3 | 4-hydroxy-N,N-dibutyltryptamine | 63065-89-4 | |
| 4-HO-DiBT | artificial | 4-OH | CH2CH(CH3)2 | CH2CH(CH3)2 | 4-hydroxy-N,N-diisobutyltryptamine | ||
| 4-HO-DsBT | artificial | 4-OH | CH(CH3)CH2CH3 | CH(CH3)CH2CH3 | 4-hydroxy-N,N-disecbutyltryptamine | 127507-01-1 | |
| 5-MeO-MET | artificial | 5-OCH3 | CH2CH3 | CH3 | 5-methoxy-N-Methyl-N-ethyltryptamine | 16977-53-0 | |
| 5-MeO-DET | artificial | 5-OCH3 | CH2CH3 | CH2CH3 | 5-methoxy-N,N-diethyltryptamine | 2454-70-8 | |
| 5-MeO-MPT | artificial | 5-OCH3 | CH3 | CH2CH2CH3 | 5-methoxy-N-methyl-N-propyltryptamine | ||
| 5-MeO-EPT | artificial | 5-OCH3 | CH2CH3 | CH2CH2CH3 | 5-methoxy-N-ethyl-N-propyltryptamine | 850032-67-6 | |
| 5-MeO-DPT | artificial | 5-OCH3 | CH2CH2CH3 | CH2CH2CH3 | 5-methoxy-N,N-dipropyltryptamine | 69496-75-9 | |
| 5-MeO-MALT | artificial | 5-OCH3 | H2C=CH-CH2 | CH3 | 5-methoxy-N-Methyl-N-allyltryptamine | 1373918-64-9 | |
| 5-MeO-DALT | artificial | 5-OCH3 | H2C=CH-CH2 | H2C=CH-CH2 | 5-methoxy-N,N-diallyltryptamine | 928822-98-4 | |
| ASR-3001 (5-MeO-iPALT) | artificial | 5-OCH3 | H2C=CH-CH2 | CH2CH(CH3)2 | 5-methoxy-N-allyl-N-isopropyltryptamine | ||
| 5-MeO-MiPT | artificial | 5-OCH3 | CH3 | CH(CH3)2 | 5-methoxy-N,N-methylisopropyltryptamine | 96096-55-8 | |
| 5,6-MeO-MiPT | artificial | 5-OCH3, 6-OCH3 | CH3 | CH(CH3)2 | 5,6-dimethoxy-N,N-methylisopropyltryptamine | ||
| 5-MeO-McPT | artificial | 5-OCH3 | CH3 | C3H5 | 5-methoxy-N-methyl-N-cyclopropyltryptamine | ||
| 5-MeO-McBT | artificial | 5-OCH3 | CH3 | C4H7 | 5-methoxy-N-methyl-N-cyclobutyltryptamine | ||
| Error creating thumbnail: Unable to save thumbnail to destination | 5-MeO-EiPT | artificial | 5-OCH3 | CH2CH3 | CH(CH3)2 | 5-methoxy-N-ethyl-N-isopropyltryptamine | 850032-66-5 |
| 5-MeO-PiPT | artificial | 5-OCH3 | CH2CH2CH3 | CH(CH3)2 | 5-methoxy-N-propyl-N-isopropyltryptamine | ||
| 5-MeO-DiPT | artificial | 5-OCH3 | CH(CH3)2 | CH(CH3)2 | 5-methoxy-N,N-diisopropyltryptamine | 4021-34-5 | |
| 5-MeO-DBT | artificial | 5-OCH3 | (CH2)3CH3 | (CH2)3CH3 | 5-methoxy-N,N-dibutyltryptamine | 73785-42-9 | |
| 5-MeO-DsBT | artificial | 5-OCH3 | CH(CH3)CH2CH3 | CH(CH3)CH2CH3 | 5-methoxy-N,N-di-sec-butyltryptamine | ||
| 5-MeS-DMT | artificial | 5-SCH3 | CH3 | CH3 | 5-methylthio-N,N-dimethyltryptamine | 5102-11-4 | |
| 5-AcO-DMT | artificial | 5-OCOCH3 | CH3 | CH3 | 5-acetoxy-N,N-dimethyltryptamine | 16977-50-7 | |
| 5-AcO-MET [35] | artificial | 5-OCOCH3 | CH3 | CH2CH3 | 5-acetoxy-N-methyl-N-ethyltryptamine | ||
| 5-AcO-DET | artificial | 5-OCOCH3 | CH2CH3 | CH2CH3 | 5-acetoxy-N,N-diethyltryptamine | ||
| 5-AcO-EPT [36] | artificial | 5-OCOCH3 | CH2CH3 | CH2CH2CH3 | 5-acetoxy-N-ethyl-N-propyltryptamine | ||
| 5-AcO-DPT | artificial | 5-OCOCH3 | CH2CH2CH3 | CH2CH2CH3 | 5-acetoxy-N,N-dipropyltryptamine | ||
| 5-AcO-MiPT | artificial | 5-OCOCH3 | CH3 | CH(CH3)2 | 5-acetoxy-N-methyl-N-isopropyltryptamine | ||
| 5-AcO-DiPT | artificial | 5-OCOCH3 | CH(CH3)2 | CH(CH3)2 | 5-acetoxy-N,N-diisopropyltryptamine | ||
| 5-Ethoxy-DMT | artificial | 5-OCH2CH3 | CH3 | CH3 | 5-ethoxy-N,N-dimethyltryptamine | 855245-09-9 | |
| 5-Ethoxy-MET | artificial | 5-OCH2CH3 | CH3 | CH2CH3 | 5-ethoxy-N-methyl-N-ethyltryptamine | ||
| 5-Ethoxy-DET | artificial | 5-OCH2CH3 | CH2CH3 | CH2CH3 | 5-ethoxy-N,N-diethyltryptamine | ||
| 5-Ethoxy-MPT | artificial | 5-OCH2CH3 | CH3 | CH2CH2CH3 | 5-ethoxy-N-methyl-N-propyltryptamine | ||
| 5-Ethoxy-EPT | artificial | 5-OCH2CH3 | CH2CH3 | CH2CH2CH3 | 5-ethoxy-N-ethyl-N-propyltryptamine | ||
| 5-Ethoxy-DPT | artificial | 5-OCH2CH3 | CH2CH2CH3 | CH2CH3 | 5-ethoxy-N,N-dipropyltryptamine | ||
| 5-Ethoxy-MiPT | artificial | 5-OCH2CH3 | CH3 | CH(CH3)2 | 5-ethoxy-N-methyl-N-isopropyltryptamine | ||
| 5-Ethoxy-EiPT | artificial | 5-OCH2CH3 | CH2CH3 | CH(CH3)2 | 5-ethoxy-N-ethyl-N-isopropyltryptamine | ||
| 5-Ethoxy-DiPT | artificial | 5-OCH2CH3 | CH(CH3)2 | CH(CH3)2 | 5-ethoxy-N,N-diisopropyltryptamine | ||
| 5-Ethoxy-DALT | artificial | 5-OCH2CH3 | H2C=CH-CH2 | H2C=CH-CH2 | 5-ethoxy-N,N-diallyltryptamine | ||
| 5-BnO-DMT | artificial | 5-OCH2C6H5 | CH3 | CH3 | 5-benzyloxy-N,N-dimethyltryptamine | 101832-88-6 | |
| 5-HO-DET | artificial | 5-OH | CH2CH3 | CH2CH3 | 5-hydroxy-N,N-diethyltryptamine | 14009-42-8 | |
| 5-HO-DPT | artificial | 5-OH | CH2CH2CH3 | CH2CH2CH3 | 5-hydroxy-N,N-dipropyltryptamine | 36288-75-2 | |
| 5-HO-MiPT | artificial | 5-OH | CH3 | CH(CH3)2 | 5-hydroxy-N-methyl-N-isopropyltryptamine | ||
| 5-HO-DiPT | artificial | 5-OH | CH(CH3)2 | CH(CH3)2 | 5-hydroxy-N,N-diisopropyltryptamine | 36288-76-3 | |
| 5-Methyl-DMT (5,N,N-TMT) | artificial | 5-CH3 | CH3 | CH3 | 5,N,N-trimethyltryptamine | 22120-39-4 | |
| 5-Ethyl-DMT | artificial | 5-CH2CH3 | CH3 | CH3 | 5-ethyl-N,N-dimethyltryptamine | 171783-25-8 | |
| 5-Isopropyl-DMT | artificial | 5-CH(CH3)2 | CH3 | CH3 | 5-isopropyl-N,N-dimethyltryptamine | 156281-04-8 | |
| 5-(t-Butyl)-DMT [37] | artificial | 5-C(CH3)3 | CH3 | CH3 | 5-(tert-butyl)-N,N-dimethyltryptamine | ||
| 5-Fluoro-DMT | artificial | 5-F | CH3 | CH3 | 5-fluoro-N,N-dimethyltryptamine | 22120-36-1 | |
| Bretisilocin (5-fluoro-MET; GM-2505) | artificial | 5-F | CH3 | CH2CH3 | 5-fluoro-N-methyl-N-ethyltryptamine | 2698331-35-8 | |
| 5-Fluoro-DET | artificial | 5-F | CH2CH3 | CH2CH3 | 5-fluoro-N,N-diethyltryptamine | ||
| 5-Fluoro-EPT | artificial | 5-F | CH2CH3 | CH2CH2CH3 | 5-fluoro-N-ethyl-N-propyltryptamine | ||
| 5-Fluoro-DPT | artificial | 5-F | CH2CH2CH3 | CH2CH2CH3 | 5-fluoro-N,N-dipropyltryptamine | ||
| 5-Fluoro-PiPT | artificial | 5-F | CH2CH2CH3 | CH(CH3)2 | 5-fluoro-N-propyl-N-isopropyltryptamine | ||
| 5-Fluoro-PcBT | artificial | 5-F | CH2CH2CH3 | CH(CH2)3 | 5-fluoro-N-propyl-N-cyclobutyltryptamine | ||
| 5-Fluoro-iPcBT | artificial | 5-F | CH(CH3)2 | CH(CH2)3 | 5-fluoro-N-isopropyl-N-cyclobutyltryptamine | ||
| 5-Fluoro-DiPT | artificial | 5-F | CH(CH3)2 | CH(CH3)2 | 5-fluoro-N,N-diisoproptryptamine | ||
| 5-Fluoro-sBALT | artificial | 5-F | CH(CH3)CH2CH3 | CH2CH=CH2 | 5-fluoro-N-sec-butyl-N-allyltryptamine | ||
| 5-Fluoro-M1MALT | artificial | 5-F | CH3 | CH(CH3)CH=CH2 | 5-fluoro-N-methyl-N-(1-methylallyl)tryptamine | ||
| 5-Chloro-DMT | artificial | 5-Cl | CH3 | CH3 | 5-chloro-N,N-dimethyltryptamine | 22120-32-7 | |
| 5-Iodo-DMT | artificial | 5-I | CH3 | CH3 | 5-iodo-N,N-dimethyltryptamine | 22120-38-3 | |
| 5-TFM-DMT | artificial | 5-CF3 | CH3 | CH3 | 5-(trifluoromethyl)-N,N-dimethyltryptamine | 2418713-32-1 | |
| 5-TFMO-DMT[38] | artificial | 5-OCF3 | CH3 | CH3 | 5-(trifluoromethoxy)-N,N-dimethyltryptamine | ||
| 5-Nitro-DMT[39] | artificial | 5-NO2 | CH3 | CH3 | 5-nitro-N,N-dimethyltryptamine | 69937-13-9 | |
| 5-CN-DMT | artificial | 5-C≡N | CH3 | CH3 | 5-cyano-N,N-dimethyltryptamine | 17380-42-6 | |
| 5-CN-DPT | artificial | 5-C≡N | CH2CH2CH3 | CH2CH2CH3 | 5-cyano-N,N-dipropyltryptamine | 74885-19-1 | |
| Almotriptan | artificial | 5-(CH2SO2N(CH2)4) | CH3 | CH3 | N,N-dimethyl-2- [5-(pyrrolidin-1-ylsulfonylmethyl)- 1H-indol-3-yl]-ethanamine | 154323-57-6 | |
| Rizatriptan | artificial | 5-(CH2(N3(CH)2)) | CH3 | CH3 | N,N-dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine | 145202-66-0 | |
| Sumatriptan | artificial | 5-(CH2SO2NHCH3) | CH3 | CH3 | 1-[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide | 103628-46-2 | |
| Zolmitriptan | artificial | 5-(CHNHC=OOCH2) | CH3 | CH3 | 5-( 4-(S)-1,3-oxazolidin-2-one)-N,N-dimethyltryptamine | 139264-17-8 | |
| 6-Fluoro-DMT | artificial | 6-F | CH3 | CH3 | 6-fluoro-N,N-dimethyltryptamine | 1511-31-5 | |
| 6-Fluoro-DET[40] | artificial | 6-F | CH2CH3 | CH2CH3 | 6-fluoro-N,N-diethyltryptamine | 2836-69-3 | |
| 6-Chloro-DMT | artificial | 6-Cl | CH3 | CH3 | 6-chloro-N,N-dimethyltryptamine | 25390-72-1 | |
| 6-Methyl-DMT | artificial | 6-CH3 | CH3 | CH3 | 6,N,N-trimethyltryptamine | ||
| 6-Hydroxy-DMT | artificial | 6-OH | CH3 | CH3 | 6-hydroxy-N,N-dimethyltryptamine | 1476-33-1 | |
| 6-Hydroxy-DET | artificial | 6-OH | CH3 | CH3 | 6-hydroxy-N,N-diethyltryptamine | 1476-59-1 | |
| 6-Methoxy-DMT | artificial | 6-OCH3 | CH3 | CH3 | 6-methoxy-N,N-dimethyltryptamine | 2426-88-2 | |
| 7-Methyl-DMT | artificial | 7-CH3 | CH3 | CH3 | 7,N,N-trimethyltryptamine | 65882-39-5 | |
| 7-Ethyl-DMT | artificial | 7-CH2CH3 | CH3 | CH3 | 7-ethyl-N,N-dimethyltryptamine | ||
| 7-Chloro-DMT | artificial | 7-Cl | CH3 | CH3 | 7-chloro-N,N-dimethyltryptamine | ||
| 7-Bromo-DMT[41] | artificial | 7-Br | CH3 | CH3 | 7-bromo-N,N-dimethyltryptamine | 74798-68-8 | |
| 7-Methoxy-DMT | artificial | 7-OCH3 | CH3 | CH3 | 7-methoxy-N,N-dimethyltryptamine | ||
| 7-Methoxy-MiPT | artificial | 7-OCH3 | CH3 | CH(CH3)2 | 7-methoxy-N-methyl-N-isopropyltryptamine | ||
| 1-Methylpsilocin | artificial | 1-CH3, 4-OH | CH3 | CH3 | 1-Methyl-3-[2-(N,N-dimethylamino)ethyl]-4-hydroxyindole | 1465-16-3 | |
| 1-Methyl-5-MeO-DiPT | artificial | 1-CH3, 5-OCH3 | CH(CH3)2 | CH(CH3)2 | 1-methyl-5-methoxy-N,N-diisopropyltryptamine | 1373882-10-0 | |
| NBoc-DMT | artificial | 1-OCOC(CH3)3 | CH3 | CH3 | 1-(t-butoxycarbonyl)-N,N-dimethyltryptamine | ||
| NB-5-MeO-MiPT | artificial | 1-OCOC(CH3)3, 5-OCH3 | CH3 | CH(CH3)2 | 1-(t-butoxycarbonyl)-5-methoxy-N-methyl-N-isopropyltryptamine | ||
| NB-5-MeO-DALT | artificial | 1-OCOC(CH3)3, 5-OCH3 | H2C=CH-CH2 | H2C=CH-CH2 | 1-(t-butoxycarbonyl)-5-methoxy-N,N-diallyltryptamine | ||
| 6-Fluoropsilocin | artificial | 4-OH,6-F | CH3 | CH3 | 4-hydroxy-6-fluoro-N,N-dimethyltryptamine | 312314-12-8 | |
| 6-Fluoro-5-MeO-DMT | artificial | 5-OCH3,6-F | CH3 | CH3 | 5-methoxy-6-fluoro-N,N-dimethyltryptamine | ||
| 5,6-Difluoro-EPT | artificial | 5-F, 6-F | CH2CH3 | CH2CH2CH3 | 5,6-difluoro-N-ethyl-N-propyltryptamine | ||
| 5-MeO-2-TMT | artificial | 2-CH3, 5-OCH3 | CH3 | CH3 | 2-(5-methoxy-2-methyl-H-indol-3-yl)-N,N-dimethylethanamine | 67292-68-6 | |
| 5-MeO-7-TMT | artificial | 5-OCH3, 7-CH3 | CH3 | CH3 | 5-Methoxy-7,N,N-trimethyltryptamine | 61018-77-7 | |
| 5-MeO-4-TMT | artificial | 4-CH3, 5-OCH3 | CH3 | CH3 | 5-Methoxy-4,N,N-trimethyltryptamine | ||
| 4-HO-5-MeO-DMT (psilomethoxin) | artificial | 4-OH, 5-OCH3 | CH3 | CH3 | 4-Hydroxy-5-methoxy-N,N-dimethyltryptamine | 2433-31-0 | |
| 4-F-5-MeO-DMT | artificial | 4-F, 5-OCH3 | CH3 | CH3 | 4-Fluoro-5-Methoxy-N,N-dimethyltryptamine | 312314-18-4 | |
| 5-MeO-7-F-MET | artificial | 5-OCH3, 7-F | CH3 | CH2CH3 | 5-Methoxy-7-Fluoro-N-methyl-N-ethyltryptamine | ||
| EMDT (2-ethyl-5-MeO-DMT) | artificial | 2-CH2CH3, 5-OCH3 | CH3 | CH3 | 2-(2-ethyl-5-methoxy-1H-indol-3-yl)-N,N-dimethylethanamine | 263744-72-5 | |
| ST-1936 (2-methyl-5-chloro-DMT) | artificial | 2-CH3, 5-Cl | CH3 | CH3 | 2-(2-methyl-5-chloro-1H-indol-3-yl)-N,N-dimethylethanamine | 1210-81-7 | |
| O-4310 (1-isopropyl-6-fluoropsilocin) | artificial | 1-CH(CH3)2, 4-OH, 6-F | CH3 | CH3 | 3-[2-(dimethylamino)ethyl]-6-fluoro-1-isopropyl-1H-indol-4-ol | 885671-63-6 | |
| CP-132,484 (4,5-DHP-1-Me-T) | artificial | 1-methyl-4,5-(OCH2CH2CH2) | H | H | 1-(2-aminoethyl)-3-methyl-8,9-dihydropyrano(3,2-e)indole | 143508-76-3 | |
| 4,5-DHP-DMT | artificial | 4,5-(OCH2CH2CH2) | CH3 | CH3 | 1-(2-dimethylaminoethyl)-8,9-dihydropyrano[3,2-e]indole | 135360-97-3 | |
| 4,5-DHF-DMT (P-3) | artificial[42] | 4,5-(CH2CH2O) | CH3 | CH3 | 2-(3,6-dihydro-2H-furo[2,3-e]indol-8-yl)-N,N-dimethylethan-1-amine | ||
| 4,5-Methylbenzoxazole-DMT (P-131) | artificial | 4,5-(OC(CH3)=N) | CH3 | CH3 | N,N-dimethyl-2-(2-methyl-6H-[1,3]oxazolo[4,5-e]indol-8-yl)ethan-1-amine | ||
| 4,5-MDO-DMT | artificial | 4,5-(OCH2O) | CH3 | CH3 | 2-(2H,6H-[1,3]Dioxolo[4,5-e]indol-8-yl)-N,N-dimethylethan-1-amine | 81249-30-1 | |
| 4,5-MDO-DiPT | artificial | 4,5-(OCH2O) | CH(CH3)2 | CH(CH3)2 | N-[2-(2H,6H-[1,3]Dioxolo[4,5-e]indol-8-yl)ethyl]-N-(propan-2-yl)propan-2-amine | 82173-82-8 | |
| 5,6-FUR-DMT (P-4) | artificial | 5,6-(CH=CHO) | CH3 | CH3 | 2-(7H-furo[3,2-f]indol-5-yl)-N,N-dimethylethan-1-amine | ||
| 5,6-MDO-DMT | artificial | 5,6-(OCH2O) | CH3 | CH3 | 2-(2H,5H-[1,3]Dioxolo[4,5-f]indol-7-yl)-N,N-dimethylethan-1-amine | ||
| 5,6-MDO-MiPT | artificial | 5,6-(OCH2O) | CH3 | CH(CH3)2 | N-[2-(2H,5H-[1,3]Dioxolo[4,5-f]indol-7-yl)ethyl]-N-methylpropan-2-amine | ||
| 5,6-MDO-DiPT | artificial | 5,6-(OCH2O) | CH(CH3)2 | CH(CH3)2 | N-[2-(2H,5H-[1,3]Dioxolo[4,5-f]indol-7-yl)ethyl]-N-(propan-2-yl)propan-2-amine | ||
| Structure | Short Name | Origin | Ring Substitution | RN1 | RN2 | Full Name | CAS # |
List of substituted α-alkyltryptamines
α-Alkyltryptamines are a group of substituted tryptamines which possess an alkyl group, such as a methyl or ethyl group, attached at the alpha carbon, and in most cases no substitution on the amine nitrogen.[43][44][45] α-Alkylation of tryptamine makes it much more metabolically stable and resistant to degradation by monoamine oxidase, resulting in increased potency and greatly lengthened half-life.[45] This is analogous to α-methylation of phenethylamine into amphetamine.[45]
Many α-alkyltryptamines are drugs, acting as monoamine releasing agents, non-selective serotonin receptor agonists, and/or monoamine oxidase inhibitors,[46][47][48][49] and produce psychostimulant, entactogen, and/or psychedelic effects.[43][44][45] The most well-known of these agents are α-methyltryptamine (αMT) and α-ethyltryptamine (αET), both of which were used clinically as antidepressants for a brief period of time in the past and are abused as recreational drugs.[44][45] In accordance with its action as a dual releasing agent of serotonin and dopamine, αET has been found to produce serotonergic neurotoxicity similarly to amphetamines like MDMA and PCA, and the same is also likely to hold true for other serotonin and dopamine-releasing α-alkyltryptamines such as αMT, 5-MeO-αMT, and various others.[50]
| Structure | Name | Chemical name | CAS # |
|---|---|---|---|
| Tryptophan | (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid | 73-22-3 | |
| 5-Hydroxytryptophan (5-HTP) | 2-amino-3-(5-hydroxy-1H-indol-3-yl)propanoic acid | 4350-09-8 | |
| αMT (AMT; Indopan) | 1-(1H-Indol-3-yl)propan-2-amine | 299-26-3 | |
| 4-HO-αMT | 3-(2-aminopropyl)-1H-indol-4-ol | 15066-09-8 | |
| 4-Methyl-αMT | 1-methyl-2-(4-methyl-1H-indol-3-yl)-ethylamine | 3569-29-7 | |
| 5-Fluoro-αMT | 1-(5-fluoro-1H-indol-3-yl)propan-2-amine | 712-08-3 | |
| 5-Chloro-αMT | 1-(5-Chloro-1H-indol-3-yl)propan-2-amine | 712-07-2 | |
| 5-HO-αMT (αMS/α-methyl-5-HT) | 3-(2-aminopropyl)-1H-indol-5-ol | 304-52-9 | |
| 5-MeO-αMT | 1-(5-methoxy-1H-indol-3-yl)propan-2-amine | 1137-04-8 | |
| 5-Ethoxy-αMT | 1-(5-ethoxy-1H-indol-3-yl)propan-2-amine | 101832-83-1 | |
| 5-Isopropoxy-αMT | 1-{5-[(propan-2-yl)oxy]-1H-indol-3-yl}propan-2-amine | ||
| 5-Allyloxy-αMT | 1-{5-[(prop-2-en-1-yl)oxy]-1H-indol-3-yl}propan-2-amine | ||
| BW-723C86 | 1-[5-(2-Thienylmethoxy)-1H-indol-3-yl]-2-propanamine | 160521-72-2 | |
| 6-Fluoro-αMT | 1-(6-fluoro-1H-indol-3-yl)propan-2-amine | 712-11-8 | |
| 7-Chloro-AMT | 1-(7-chloro-1H-indol-3-yl)propan-2-amine | 711-99-9 | |
| AL-37350A (4,5-DHP-αMT) | (S)-(+)-1-(2-Aminopropyl)-8,9-dihydropyrano[3,2-e]indole | 362603-40-5 | |
| Compound 5 [51] | 1-(3H-benzo[e]indol-1-yl)propan-2-amine | ||
| αET | 1-(1H-indol-3-yl)butan-2-amine | 2235-90-7 | |
| 4-Methyl-αET | 1-(4-Methyl-1H-indol-3-yl)butan-2-amine | 28289-30-7 | |
| 4-HO-αET | 1-(4-hydroxy-1H-indol-3-yl)butan-2-amine | 28289-28-3 | |
| 5-Fluoro-αET | 1-(5-fluoro-1H-indol-3-yl)butan-2-amine | 1380137-98-3 | |
| 5-Methyl-αET | 1-(5-methyl-1H-indol-3-yl)butan-2-amine | 1380148-21-9 | |
| 5-MeO-αET | 1-(5-methoxy-1H-indol-3-yl)butan-2-amine | 4765-10-0 | |
| 7-Methyl-αET | 1-(7-methyl-1H-indol-3-yl)butan-2-amine | 13712-80-6 | |
| N-Methyl-5-MeO-αMT (α,N,O-TMS/α,N,O-trimethyl-5-HT) | [1-(5-methoxy-1H-indol-3-yl)propan-2-yl](methyl)amine | 4822-13-3 | |
| Indolylpropylaminopentane (IPAP; α,N-DPT) | 1-(1H-indol-3-yl)-N-propylpentan-2-amine | ||
| N,N-Dimethyl-αMT (α,N,N-TMT) | (2-(1H-Indol-3-yl)-1-methyl-ethyl)dimethylamine | 4761-32-4 | |
| N,N-Dimethyl-5-MeO-αMT (5-MeO-α,N,N-TMT) | (2-(5-methoxy-1H-Indol-3-yl)-1-methyl-ethyl)dimethylamine | 101831-90-7 | |
| α-Methyl-DiPT | (2-(1H-Indol-3-yl)-1-methyl-ethyl)diisopropylamine | ||
| MPMI[52] | 3-[(1-methylpyrrolidin-2-yl)methyl]-1H-indole | 143321-54-4 | |
| Lucigenol (4-HO-MPMI) | (R)-3-(N-methylpyrrolidin-2-ylmethyl)-4-hydoxyindole | 250672-65-2 | |
| 5-MeO-MPMI (CP-108509) | 5-Methoxy-3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-1H-indole | 143321-57-7 | |
| 5F-MPMI[53] | (R)-5-fluoro-3-[(1-methylpyrrolidin-2-yl)methyl]-1H-indole | ||
| 5-Br-MPMI | 5-bromo-3-[(1-methylpyrrolidin-2-yl)methyl]-1H-indole | 143322-57-0 | |
| Eletriptan | 3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(benzenesulfonyl)ethyl]-1H-indole | 143322-58-1 | |
| Z5247692566[27][54] | 4-[(3,3-dimethyloxolan-2-yl)methyl]-3-[(1H-indol-3-yl)methyl]morpholine | ||
| BK-NM-AMT (α,N-dimethyl-β-ketotryptamine)[55][56][57] | 1-(1H-indol-3-yl)-2-(methylamino)propan-1-one | ||
| BK-5F-NM-AMT (5-fluoro-α,N-dimethyl-β-ketotryptamine)[58][59][60][57] | 1-(5-fluoro-1H-indol-3-yl)-2-(methylamino)propan-1-one | ||
| BK-5Cl-NM-AMT (5-chloro-α,N-dimethyl-β-ketotryptamine)[60][61][62] | 1-(5-chloro-1H-indol-3-yl)-2-(methylamino)propan-1-one | ||
| BK-5Br-NM-AMT (5-bromo-α,N-dimethyl-β-ketotryptamine)[60][63][64] | 1-(5-bromo-1H-indol-3-yl)-2-(methylamino)propan-1-one |
List of substituted β-ketotryptamines
A number of β-ketotryptamines (beta-ketotryptamines) are known.[55][57][60] These compounds are α-alkyl-β-ketotryptamines and are analogous to the cathinones (β-ketoamphetamines) of the related phenethylamine family. Known β-ketotryptamines include BK-NM-AMT, BK-5F-NM-AMT, BK-5Cl-NM-AMT, and BK-5Br-NM-AMT.[55][57][60] They act as monoamine releasing agents.[55][57][60]
Cyclized tryptamines
Examples of cyclized tryptamines include:
- β-Carbolines such as harmala alkaloids like harmaline
- Ibogalogs (hexahydroazepinoindoles) such as ibogainalog, tabernanthalog, PNU-22394, and PHA-57378
- Iboga alkaloids like ibogaine, noribogaine, ibogamine, and tabernanthine
- Ergolines and lysergamides such as lysergic acid diethylamide (LSD) and ergot alkaloids like ergine (lysergic acid amide; LSA)
- Partial ergolines and lysergamides like RU-27849, FHATHBIN, NDTDI, and CT-5252
- Mitragyna alkaloids such as mitragynine
- Yohimbans such as Rauvolfia and Corynanthe alkaloids like yohimbine and rauwolscine
- Pertines (phenylpiperazinylethylindoles) like alpertine, milipertine, oxypertine, and solypertine
- Imidazolylindoles like AGH-107, AGH-192, and AH-494
- Piperidinylethylindoles like pip-T
- Pyrrolidinylethylindoles like pyr-T, 4-HO-pyr-T, 5-MeO-pyr-T, and 4-F-5-MeO-pyr-T
- Pyrrolidinylmethylindoles like MPMI, 4-HO-MPMI (lucigenol), 5F-MPMI, 5-MeO-MPMI, CP-135807, and eletriptan
- Tetrahydropyridinylindoles like RS134-49 (4-Me-THPI), RU-28253 (5-MeO-THPI), and NEtPhOH-THPI
- Tetrahydrocarbazolamines like ciclindole, flucindole, frovatriptan, LY-344864, and ramatroban
- Tetrahydropyrroloquinolines like bufothionine and O-methylnordehydrobufotenine
- Others like barettin, cyclic 3-hydroxymelatonin, and metralindole
Other closely related cyclized tryptamine-like compounds include the following:
- Piperidinylindoles like SN-22, BRL-54443, naratriptan, LY-334370, and sertindole
- Tetrahydropyridinylindoles like RU-24969, EMD-386088, and LY-367,265
- Tetrahydropyridinylindazoles like VU6067416
- Tetrahydropyridinylpyrrolopyridines like (R)-69, (R)-70, and CP-94253
- Pyridopyrroloquinoxalines (tetracyclic γ-carbolines) like lumateperone, IHCH-7113, IHCH-7086, and ITI-1549
Related compounds
A number of related compounds are known, with a similar structure but having the indole core flipped (isotryptamines) and/or replaced with related cores such as indene, indoline, indazole, indolizine, benzothiophene, or benzofuran. Like tryptamines, these related compounds are primarily active as agonists at the 5-HT2 family of serotonin receptors, with applications in the treatment of glaucoma, cluster headaches, or as anorectics.
| Structure | Name | Chemical name | CAS # |
|---|---|---|---|
| C-DMT[65] | 2-(3H-inden-1-yl)-N,N-dimethylethanamine | ||
| Dimemebfe (5-MeO-BFE) | 2-(5-Methoxy-1-benzofuran-3-yl)-N,N-dimethylethanamine | 140853-58-3 | |
| 5-MeO-DiBF | N-[2-(5-Methoxy-1-benzofuran-3-yl)ethyl]-N-(propan-2-yl)propan-2-amine | ||
| 3-APB | 3-(2-aminopropyl)benzofuran | 105909-13-5 | |
| 3-APBT (SKF-6678) | 1-(1-benzothiophen-3-yl)propan-2-amine | 1201-27-0 | |
| Mebfap (5-MeO-3-APB) | 3-(2-aminopropyl)-5-methoxybenzofuran | 140853-59-4 | |
| Isotryptamine (isoT) | 2-indol-1-ylethanamine | 13708-58-2 | |
| isoAMT | 1-indol-1-ylpropan-2-amine | 1227465-67-9 | |
| (S)-5,6-Difluoro-isoAMT [66] | (S)-1-(5,6-difluoroindol-1-yl)propan-2-amine | ||
| Ro60-0175 ((S)-5-F-6-Cl-isoAMT) | (S)-(6-chloro-5-fluoro-1H-indol-1-yl)propan-2-amine | 169675-09-6 | |
| isoDMT | 2-indol-1-yl-N,N-dimethylethanamine | 87482-09-5 | |
| 5-MeO-isoDMT | 2-(5-methoxyindol-1-yl)-N,N-dimethylethanamine | 244122-80-3 | |
| 6-MeO-isoDMT | 2-(6-methoxyindol-1-yl)-N,N-dimethylethanamine | 87482-11-9 | |
| Zalsupindole (DLX-001; AAZ-A-154; (R)-5-MeO-α-Me-isoDMT) | (2R)-1-(5-methoxy-1H-indol-1-yl)-N,N-dimethylpropan-2-amine | 2481740-94-5 | |
| 2ZEDMA | 2-indolizin-1-yl-N,N-dimethylethanamine | ||
| 1ZP2MA | 1-indolizin-1-yl-N-methylpropan-2-amine | ||
| 1Z2MAP1O | 1-indolizin-3-yl-2-(methylamino)propan-1-one | 2110204-31-2 | |
| Example 16 [67][68] | 1-(7-methoxyimidazo[1,5-a]pyridin-3-yl)-N,N-dimethylpropan-2-amine | ||
| Example 1 [69] | 1-(3-methyl-8,9-dihydropyrano[2,3-g]indol-1(7H)-yl)propan-2-amine | ||
| VER-3323 | (2S)-1-(6-bromo-2,3-dihydroindol-1-yl)propan-2-amine | 259857-99-3 | |
| AL-34662 (indazole-5-HO-AMT) | 1-((S)-2-Aminopropyl)-1H-indazol-6-ol | 210580-75-9 | |
| O-Methyl-AL-34662 (indazole-5-MeO-AMT) | 1-((S)-6-methoxy-2-aminopropyl)-1H-indazole | 210580-60-2 | |
| 7-Methyl-AL-34662 | 1-((S)-2-Aminopropyl)-7-methyl-1H-indazol-6-ol | 874668-67-4 | |
| 7-Chloro-AL-34662 | 1-((S)-2-Aminopropyl)-7-chloro-1H-indazol-6-ol | 874881-86-4 | |
| AL-38022A | (S)-2-(8,9-dihydro-7H-pyrano[2,3-g]indazol-1-yl)-1-methylethylamine | 478132-11-5 | |
| Example 9 [70] | (S)-α-methyl-pyrano[2,3-g]indazole-1(7H)-ethanamine | 478132-12-6 | |
| Example 3 [71] | (S)-7,8-dihydro-α-methyl-1H-[1,4]dioxino[2,3-g]indazole-1-ethanamine | 890087-75-9 | |
| Example 1 [72] | (S)-8,9-dihydro-α,9-dimethylpyrazolo[3,4-f][1,4]benzoxazine-1(7H)-ethanamine | 1373917-69-1 | |
| YM-348 | (2S)-1-(7-ethyl-1H-furo[2,3-g]indazol-1-yl)propan-2-amine | 372163-84-3 | |
| 2-Desethyl-YM-348 [73] | (2S)-1-(1H-furo[2,3-g]indazol-1-yl)propan-2-amine | 748116-94-1 | |
| I-32 [74] | 3-(1-methylpyrrolidin-3-yl)-1H-indol-4-ol | ||
| 2-Azapsilocin (Psilocin indazole analogue, P-6)[75] | 3-[2-(dimethylamino)ethyl]-1H-indazol-4-ol | ||
| 4-Aza-5-MeO-DPT (P-11) | N-[2-(5-methoxy-1H-pyrrolo[3,2-b]pyridin-3-yl)ethyl]-N-propylpropan-1-amine | ||
| 5-Aza-4-MeO-DiPT (P-36) | N-[2-(4-methoxy-1H-pyrrolo[3,2-c]pyridin-3-yl)ethyl]-N-(propan-2-yl)propan-2-amine | ||
| 7-Aza-5-MeO-DiPT (P-19) | N-[2-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)ethyl]-N-(propan-2-yl)propan-2-amine | ||
| RS134-49 (4-Me-THPI) | 4-methyl-3-(1,2,3,6-tetrahydropyridin-5-yl)-1H-indole | 2945139-94-4 | |
| RU-28253 (5-MeO-THPI) | 5-methoxy-3-(1,2,3,6-tetrahydropyridin-5-yl)-1H-indole | ||
| NEtPhOH-THPI (compound 24c) | 3-(1-(2-hydroxyphenylethyl)-1,2,3,6-tetrahydropyridin-5-yl)-1H-indole | ||
| VU6067416[76] | 3-(1,2,5,6-tetrahydropyridin-3-yl)-5-bromo-1H-indazole | 3027515-24-5 | |
| (R)-69 | 3-[(5R)-5-methyl-1,2,5,6-tetrahydropyridin-3-yl]-1H-pyrrolo[2,3-b]pyridine | 2765652-48-8 | |
| SN-22 | 3-(1-methylpiperidin-4-yl)-1H-indole | 17403-07-5 | |
| RU-24,969 | 5-methoxy-3-(1,2,5,6-tetrahydro-4-pyridinyl)-1H-indole | 107008-28-6 | |
| EMD-386088 | 5-chloro-2-methyl-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole | 54635-62-0 |
Overview table
Template:Simple tryptamines and their common derivatives
See also
- Substituted β-carboline
- Ibogalog
- Iboga alkaloid
- Lysergamide
- TiHKAL
- List of miscellaneous 5-HT2A receptor agonists
- Substituted isotryptamine
- Indazolylethylamine
- Indolizinylethylamine
- Tetrahydropyridinylpyrrolopyridine
- Substituted 2-aminoindane
- Substituted amphetamine
- Substituted benzofuran
- Substituted cathinone
- Substituted methylenedioxyphenethylamine
- Substituted phenethylamine
- 2C, DOx, 25-NB
References
- ↑ Chemistry, University of; Prague, Technology. "Concentrations of psychoactive compounds in mushrooms found to be extremely variable" (in en). https://phys.org/news/2022-12-psychoactive-compounds-mushrooms-extremely-variable.html.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 Shulgin, Alexander; Shulgin, Ann (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252. http://www.erowid.org/library/books_online/tihkal/tihkal.shtml.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 "Structure-activity relationships of the classic hallucinogens and their analogs". NIDA Res Monogr 146: 74–91. 1994. PMID 8742795. https://archives.nida.nih.gov/sites/default/files/monograph146.pdf#page=79.
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 "Basic Pharmacology and Effects". Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. 2003. pp. 67–137. ISBN 978-0-12-433951-4. https://web.archive.org/web/20250223164514/https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=6bb3a7499da8e9852b39cd4db16891147c83f5c6.
- ↑ "Chemistry of Psychotomimetics". Psychotropic Agents, Part III: Alcohol and Psychotomimetics, Psychotropic Effects of Central Acting Drugs. Handbook of Experimental Pharmacology. 55 / 3. Berlin: Springer Berlin Heidelberg. 1982. pp. 3–29. doi:10.1007/978-3-642-67770-0_1. ISBN 978-3-642-67772-4. OCLC 8130916. https://bitnest.netfirms.com/external/10.1007/978-3-642-67770-0_1.
- ↑ Alexander T. Shulgin (1980). "Hallucinogens". Burger's Medicinal Chemistry. 3 (4 ed.). New York: Wiley. pp. 1109–1137. ISBN 978-0-471-01572-7. OCLC 219960627. https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=6ac0c892ee380436f614d3aae0686ef617b2e0c5.
- ↑ 7.0 7.1 7.2 7.3 "Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics". Int J Neuropsychopharmacol 21 (10): 926–931. October 2018. doi:10.1093/ijnp/pyy047. PMID 29850881.
- ↑ 8.0 8.1 8.2 8.3 Halberstadt, Adam L.; Chatha, Muhammad; Klein, Adam K.; Wallach, Jason; Brandt, Simon D. (May 2020). "Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species". Neuropharmacology 167. doi:10.1016/j.neuropharm.2019.107933. PMID 31917152. PMC 9191653. https://web.archive.org/web/20250326111621/http://usdbiology.com/cliff/Courses/Advanced%20Seminars%20in%20Neuroendocrinology/Serotonergic%20Psychedelics%2020/Halberstadt%2020%20Neuropharm%20potency%20of%20hallucinogens%20%20head-twitch.pdf. "Table 4 Human potency data for selected hallucinogens. [...]".
- ↑ 9.0 9.1 9.2 9.3 Ballentine, Galen; Friedman, Samuel Freesun; Bzdok, Danilo (March 2022). "Trips and neurotransmitters: Discovering principled patterns across 6850 hallucinogenic experiences". Sci Adv 8 (11). doi:10.1126/sciadv.abl6989. PMID 35294242. Bibcode: 2022SciA....8L6989B.
- ↑ "The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides". Psychopharmacology (Berl) 239 (6): 1783–1796. June 2022. doi:10.1007/s00213-022-06142-4. PMID 35487983.
- ↑ 11.0 11.1 11.2 11.3 11.4 11.5 "Biochemistry and pharmacology of tryptamines and beta-carbolines. A minireview". J Psychoactive Drugs 16 (4): 347–358. 1984. doi:10.1080/02791072.1984.10472305. PMID 6394730. https://bitnest.netfirms.com/external/10.1080/02791072.1984.10472305.
- ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedLiechtiHolze2022 - ↑ 13.0 13.1 Cite error: Invalid
<ref>tag; no text was provided for refs namedHolzeSinghLiechti2024 - ↑ "Toxicology and Analysis of Psychoactive Tryptamines". International Journal of Molecular Sciences 21 (23): 9279. December 2020. doi:10.3390/ijms21239279. PMID 33291798. "4-OH-DPT is the 4-hydroxylated DPT derivative first synthesized by Shulgin et al. [82]. 4-OH-DPT is a light beige or white powder [54] that acts as a 5-HT2A partial agonist. 4-OH-DPT also shares structural similarity with psilocin [83]. Effects are dose dependent, with onset at 15–45 min and duration of 5–8 h. According to user reports, synthetic 4-OH-DPT produces visual effects and hallucinatory states [84].".
- ↑ "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study". J Clin Psychopharmacol 45 (5): 441–453. 2025. doi:10.1097/JCP.0000000000002047. PMID 40685873.
- ↑ "Pharmañopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine". Journal of Psychoactive Drugs 33 (3): 273–281. 2001. doi:10.1080/02791072.2001.10400574. PMID 11718320.
- ↑ "Shamanic-Snuff Psychonautica: Pharmañopo: Bufotenine—Psychonautics". Shamanic Snuffs or Entheogenic Errhines. Entheobotanica. 2001. pp. 99–116 (105–112, 114–115). ISBN 978-1-888755-02-2. OCLC 56061312. https://archive.org/details/vdocuments.mx_unknown-55b347d139b58/page/n51/mode/1up. Retrieved 24 January 2025.
- ↑ "A New One-Hour Talk On 5-MeO-DMT". Patreon. 1 December 2022. https://www.patreon.com/posts/new-one-hour-on-75373519. "[Morris:] Bufotenine is a drug that I have tried. I've tried isolated pure bufotenine and it is a psychedelic that is both pharmacologically and experientially and chemically intermediate between DMT and 5-MeO-DMT. So it has a longer duration than actually both 5-MeO-DMT and DMT. It's yet less visual than DMT but more visual than 5-MeO-DMT, so it's kind of like in-between the two. It's also very nauseating, which is the main reason that people seem not to enjoy it very much. But it is a classical psychedelic drug that produces visionary effects. And Jonathan Ott actually liked the effect of it quite a bit."
- ↑ Hamilton Morris (1 September 2021). "PODCAST 28: A talk with Jonathan Ott". The Hamilton Morris Podcast (Podcast). Patreon. Event occurs at 49:20–50:36. Retrieved 20 January 2025.
[Morris:] I've used [bufotenine] a couple times, once at 50 milligrams of the freebase snorted. [...] I found it to be extremely nauseating. I found it to be qualitatively intermediate between 5-MeO-DMT and DMT in that it was more visual than my experiences with 5-MeO-DMT but less visual than my typical experiences with DMT. It had a longer duration than 5-MeO-DMT and maybe even a longer duration than DMT as well. It was about an hour. Although I don't have all that much experience snorting DMT freebase.
- ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedOtt1999 - ↑ "Unusual Analogues: Drugs Used by Gordon Todd Skinner". This Land Press. http://thislandpress.com/2013/07/25/unusual-analogues-drugs-used-by-gordon-todd-skinner/.
- ↑ Hamilton Morris (29 April 2025). "POD 126: The Return of Psychedelic Selenium with Dr. Josh Hartsel". The Hamilton Morris Podcast (Podcast). Patreon. Event occurs at 1:33:53–1:35:50.
[...] [Hartsel:] The α,N,N-Dimethyl[tryptamine]. [Morris:] Oh yeah, I've made it and tried it actually. [Hartsel:] Oh you did? [Morris:] Yeah, yeah. [Hartsel:] Oh, well what did it do? [Morris:] It is active, it's an active psychedelic. It's reduced potency. I never got it to a dose where it produced particularly interesting effects. I can look up the exact dose. I think it was like... the only thing I remember is that I felt like it was making me sneeze a lot. But it was very pleasant. Nothing bad happened. But the dose just wasn't high enough. I think I took maybe 40 mg. So it was much less potent than AMT orally. The other issue of course is that it could be a prodrug of N-methyl-AMT, which is active, or AMT itself maybe. [...]
- ↑ "Sea DMT: God Molecule or Barnacle Repellent?". Vice. 26 March 2013. https://www.vice.com/en/article/sea-dmt-000481-v20n3/.
- ↑ Marek GJ, Makai-Bölöni S, Umbricht D, Christian EP, Winters J, Dvorak D, Raines S, Hughes ZA, Austin EW, Klein AK, Leong W, Krol FJ, Graaf AJV, Juachon MJ, Otto ME, Borghans LGJM, Jacobs G, Kruegel AC, Sporn J. A novel psychedelic 5-HT2A receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer. J Psychopharmacol. 2025 Oct 16:2698811251378512. doi:10.1177/02698811251378512 PMID 41099491
- ↑ "5-HT2 receptor binding, functional activity and selectivity in N-benzyltryptamines". PLOS ONE 14 (1). 2019. doi:10.1371/journal.pone.0209804. PMID 30629611. Bibcode: 2019PLoSO..1409804T.
- ↑ Jensen N. Tryptamines as Ligands and Modulators of the Serotonin 5-HT2A Receptor and the Isolation of Aeruginascin from the Hallucinogenic Mushroom Inocybe aeruginascens. PhD thesis, University of Göttingen, 2004
- ↑ 27.0 27.1 "AlphaFold2 structures template ligand discovery". bioRxiv. December 2023. doi:10.1101/2023.12.20.572662. PMID 38187536.
- ↑ 28.0 28.1 "Towards "unmakable" psychedelics: SAR exploration of psilocin analogs obtained by a HATU-mediated amide coupling strategy". European Journal of Medicinal Chemistry Reports 15. 2025. doi:10.1016/j.ejmcr.2025.100278.
- ↑ "Analogues of Psilocin and Lysergic acid diethylamide I. Chloro, Nitro, and Amino Derivatives of 3-Substituted Indoles.". Canadian Journal of Chemistry 41 (10): 2585–2590. October 1963. doi:10.1139/v63-378.
- ↑ "Investigation of the Structure-Activity Relationships of Psilocybin Analogues". ACS Pharmacology & Translational Science 4 (2): 533–542. April 2021. doi:10.1021/acsptsci.0c00176. PMID 33860183.
- ↑ "Psilacetin derivatives: fumarate salts of the meth-yl-ethyl, meth-yl-allyl and diallyl variants of the psilocin prodrug". Acta Crystallographica Section E 77 (Pt 2): 101–106. February 2021. doi:10.1107/S2056989021000116. PMID 33614134. Bibcode: 2021AcCrE..77..101P.
- ↑ Sherwood AM, Burkhartzmeyer EK, Williamson SE, Baumann MH, Glatfelter GC (Jan 2024). "Psychedelic-like Activity of Norpsilocin Analogues". ACS Chem Neurosci 15 (2): 315–327. doi:10.1021/acschemneuro.3c00610. PMID 38189238.
- ↑ Banister S, Jorgensen W, Jinlong T, "Compounds", WO patent 2023115167, published 29 June 2023
- ↑ Kozikowski A, Shaprio G, Tueckmantel W, McCorvy J, "3-(2-(Aminoethyl)-indol-4-ol derivatives, methods of preparation thereof, and the use as 5-HT2 receptor modulators", WO patent 2021179091, published 16 September 2021, assigned to Bright Minds Biosciences Inc.and The Medical College Of Wisconsin Inc.
- ↑ Stamets PE, "Tryptamine Compositions for Enhancing Neurite Outgrowth.", WO patent 2021101926, published 2021-05-27, assigned to Stamets Paul Edward.
- ↑ Kruegel AC, Sporn J, "Specific Tryptamines for use in the Treatment of Mood Disorders.", WO patent 2021168082, published 26 August 2021
- ↑ "N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist". Journal of Medicinal Chemistry 42 (3): 526–31. February 1999. doi:10.1021/jm9805945. PMID 9986723.
- ↑ Kruegel AC, "Novel Tryptamines and Methods of Treating Mood Disorders", WO patent 2022235927, published 10 November 2022, assigned to Gilgamesh Pharmaceuticals, Inc.
- ↑ "The synthesis of nitro-and aminoindoles analogous to serotonin.". Journal of the American Chemical Society 75 (8): 1877–1881. April 1953. doi:10.1021/ja01104a029.
- ↑ "5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens". Pharmacology, Biochemistry, and Behavior 72 (1–2): 29–37. May 2002. doi:10.1016/s0091-3057(01)00720-1. PMID 11900766.
- ↑ "Studies on several 7-substituted N,N-dimethyltryptamines". Journal of Medicinal Chemistry 23 (11): 1222–6. November 1980. doi:10.1021/jm00185a014. PMID 6779006.
- ↑ Banister S, Jorgensen W, Jinlong T, "Compounds", WO patent 2023115166, published 29 June 2023
- ↑ 43.0 43.1 Principles of Addiction Medicine. Lippincott Williams & Wilkins. 2009. pp. 216–218. ISBN 978-0-7817-7477-2. https://books.google.com/books?id=j6GGBud8DXcC&pg=PT245.
- ↑ 44.0 44.1 44.2 Hallucinogens: A Forensic Drug Handbook. Academic Press. 2003. pp. 102–. ISBN 978-0-12-433951-4. https://books.google.com/books?id=l1DrqgobbcwC&pg=PA102.
- ↑ 45.0 45.1 45.2 45.3 45.4 Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. 24 January 2012. pp. 641–. ISBN 978-1-60913-345-0. https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA641.
- ↑ "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain". European Journal of Pharmacology 559 (2–3): 132–7. March 2007. doi:10.1016/j.ejphar.2006.11.075. PMID 17223101.
- ↑ "Alpha-ethyltryptamines as dual dopamine-serotonin releasers". Bioorganic & Medicinal Chemistry Letters 24 (19): 4754–4758. October 2014. doi:10.1016/j.bmcl.2014.07.062. PMID 25193229.
- ↑ "In vitro screening of psychoactive drugs by [(35)S]GTPgammaS binding in rat brain membranes". Biological & Pharmaceutical Bulletin 30 (12): 2328–33. December 2007. doi:10.1248/bpb.30.2328. PMID 18057721.
- ↑ "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insluin secretion". Diabetologia 11 (6): 487–94. December 1975. doi:10.1007/bf01222097. PMID 1107123.
- ↑ "Reduction in brain serotonin markers by alpha-ethyltryptamine (Monase)". European Journal of Pharmacology 200 (1): 187–90. July 1991. doi:10.1016/0014-2999(91)90686-K. PMID 1722753.
- ↑ "Evaluation of isotryptamine derivatives at 5-HT(2) serotonin receptors". Bioorganic & Medicinal Chemistry Letters 12 (2): 155–8. January 2002. doi:10.1016/s0960-894x(01)00713-2. PMID 11755343.
- ↑ Macor JE, Wythes MJ, "Indole derivatives", US patent 5607951, issued 4 March 1997, assigned to Pfizer, Inc.
- ↑ Wallach J, Dybek M, "Fluorinated Tryptamine Compounds, Analogues Thereof, and Methods Using Same.", WO patent 2022256554, published 8 December 2022, assigned to University Of The Sciences.
- ↑ "AlphaFold found thousands of possible psychedelics. Will its predictions help drug discovery?". Nature News 626 (7997): 14–15. 18 January 2024. doi:10.1038/d41586-024-00130-8. PMID 38238624. Bibcode: 2024Natur.626...14C.
- ↑ 55.0 55.1 55.2 55.3 "The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes". Psychopharmacology (Berl) 236 (3): 915–924. March 2019. doi:10.1007/s00213-018-5063-9. PMID 30341459.
- ↑ "1-(1H-indol-3-yl)-2-(methylamino)propan-1-one". https://pubchem.ncbi.nlm.nih.gov/compound/82282492.
- ↑ 57.0 57.1 57.2 57.3 57.4 & Sean Dalziel"Specialized combinations for mental disorders or mental enhancement" US patent 20240335414, published 10 October 2024
- ↑ "1-(5-fluoro-1H-indol-3-yl)-2-(methylamino)propan-1-one". https://pubchem.ncbi.nlm.nih.gov/compound/162765676.
- ↑ "β-Oxo-5-fluoro-α-methyl-NMT". 10 November 2024. https://isomerdesign.com/pihkal/explore/12714.
- ↑ 60.0 60.1 60.2 60.3 60.4 60.5 Matthew Baggott, "Advantageous tryptamine compositions for mental disorders or enhancement", WO patent 2022061242, published 2023 March 24, assigned to Tactogen
- ↑ "1-(5-chloro-1H-indol-3-yl)-2-(methylamino)propan-1-one". https://pubchem.ncbi.nlm.nih.gov/compound/162765502.
- ↑ "β-Oxo-5-chloro-α-methyl-NMT". 10 November 2024. https://isomerdesign.com/pihkal/explore/12715.
- ↑ "1-(5-bromo-1H-indol-3-yl)-2-(methylamino)propan-1-one". https://pubchem.ncbi.nlm.nih.gov/compound/162765532.
- ↑ "β-Oxo-5-bromo-α-methyl-NMT". 10 November 2024. https://isomerdesign.com/pihkal/explore/12725.
- ↑ "PiHKAL·info". 11 November 2024. https://isomerdesign.com/pihkal/explore/5070.
- ↑ "Evaluation of isotryptamine derivatives at 5-HT(2) serotonin receptors". Bioorg Med Chem Lett 12 (2): 155–158. January 2002. doi:10.1016/s0960-894x(01)00713-2. PMID 11755343. "Detailed re-examination of a compound previously reported to display 100-fold 5-HT2C selectivity [i.e., S(+)-5,6-difluoro-α-methylisotryptamine] revealed that its selectivity versus 5-HT2A receptors was, at best, only 10-fold.".
- ↑ Kargbo RB (Jan 2024). "Neuropharmacological Advances: Harnessing 5-HT2A Receptor Modulators and Psychoplastogens". ACS Med Chem Lett 15 (2): 171–173. doi:10.1021/acsmedchemlett.4c00003. PMID 38352827.
- ↑ Powell NA, Chytil M. Imidazopyridine psychoplastogens and uses thereof. WO 2023/114844
- ↑ Chen HH, May JA, "Pyranoindoles for treating glaucoma", US patent granted 7012090, published 17 March 2000, issued 14 March 2006, assigned to Alcon, Inc.
- ↑ Chen HH, May JA, Severns BS, "Pyranoindazoles and their use for the treatment of glaucoma", US patent granted 6881749, published 3 June 2004, issued 19 April 2005, assigned to Alcon, Inc.
- ↑ Chen HH, May JA, "Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma", US patent granted 7425572, published 8 June 2006, issued 16 September 2008, assigned to Alcon, Inc.
- ↑ "Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma" US patent granted 7268131, published 15 December 2005, issued 11 September 2007, assigned to Alcon, Inc.
- ↑ "Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists". Bioorganic & Medicinal Chemistry 16 (4): 1966–82. February 2008. doi:10.1016/j.bmc.2007.10.100. PMID 18035544.
- ↑ Slassi A, Araujo J, Higgins G, "3-Cyclic Amine-Indole Derivatives as Serotonergic Agents for the Treatment of CNS Disorders.", WO patent 2022120475, published 16 June 2022
- ↑ Banister S, Jorgensen W, Jinlong T, "Compounds", WO patent 2023115165, published 29 June 2023
- ↑ Jayakodiarachchi N (2024). "Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists". ACS Med. Chem. Lett. 15 (2): 302–309. doi:10.1021/acsmedchemlett.3c00566.
Template:Chemical classes of psychoactive drugs
